GB Patent

GB0009522D0 — Composition

Assigned to SmithKline Beecham Ltd · Expires 2000-06-07 · 26y expired

What this patent protects

A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.

USPTO Abstract

A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.

Drugs covered by this patent

Patent Metadata

Patent number: GB0009522D0
Jurisdiction: GB
Classification: —
Expires: 2000-06-07
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.